Canabo Medical Inc.
Canabo Medical Inc.
- ISIN: CA1348001019
- Land: .
Nachricht vom 29.12.2017 | 20:54
Canabo Medical Inc. Announces Financing Syndicate for $20 Million Offering in Conjuntion with the Aleafia Inc Business Combination
DGAP-News: Canabo Medical Inc. / Key word(s): Miscellaneous
Halifax, Nova Scotia--(Newsfile Corp. - December 29, 2017) - Further to press release disseminated on December 22, 2017, Canabo Medical Inc. (TSXV: CMM) ('Canabo' or the 'Company') in conjunction with Aleafia Inc, 'Aleafia') is pleased to announce the participants of the syndicate (the 'Syndicate') as described in the earlier business combination release.
The Offering will consist of Mackie Research as co-lead agent with Canaccord Genuity Corp.. Clarus Securities and Power One Capital Markets Ltd. are also participating in the syndicate.
Concurrently with the proposed business combination transaction described in the December 22, 2017 release, Aleafia intends to complete a brokered private placement of subscription receipts ('Subscription Receipts') on a 'best efforts' basis for gross proceeds of approximately $20,000,000 (the 'Aleafia Private Placement') at an offering price of $1.25 per Subscription Receipt. The Agents (as defined below) will have the option exercisable any time up to 24 hours prior to the closing of the Offering to increase the size of the Aleafia Private Placement by up to 15% (the 'Over-Allotment Option'), for a total of up to $23,000,000. Each Subscription Receipt will, following the completion of the Aleafia Private Placement, and the satisfaction of certain escrow release conditions, entitle the holder to receive, without payment of additional consideration or taking of further action, one (1) unit consisting of (1) common share and one half of one common share purchase warrant in the capital of the Resulting Issuer. Each whole warrant is exercisable into one (1) common share in the Resulting Issuer at a price of $1.75 for 18 months following issuance.
Overview of Aleafia
Aleafia operates the Aleafia Total Health Network (the 'Aleafia Network') in Vaughan, Ontario. Aleafia seeks to make a difference in cannabinoid therapy delivery by providing an interconnected medical service model. While most clinical programs are geared primarily towards post injury rehabilitation, the Aleafia Network is focused on the strong link between early intervention and successful treatment. The intent is to manage health through a patient focused, assessment based, and interdisciplinary resourced organization.
Recently, Aleafia completed a transaction under which it acquired 100% of the issued and outstanding shares of 755064 Ontario Inc. (operating as AeroFarms Canada), a licensed producer under the Health Canada Access to Cannabis for Medical Purposes Regulations (ACMPR), as well as the land and building in Scugog Ontario where the facility operates. Aleafia acquired AeroFarms Canada to directly support the Aleafia Network.
Canabo wholly owns and operates Cannabinoid Medical Clinics, or CMClinics, Canada's largest physician led referral-only clinics for medical cannabis. Established in 2014, Canabo now has 22 clinics across Canada, with additional locations planned to open in 2018. Canabo operates referral-only medical clinics dedicated to evaluating the suitability of prescribing, and monitoring cannabinoid treatments for patients suffering from chronic pain and disabling illnesses. Clinics operated by Canabo are staffed by physicians and qualified health care practitioners specifically trained to assess patient suitability for cannabinoid treatment, recommend treatment regimes, and monitor treatment progress.
In accordance with Exchange policy, the Company's shares are currently halted from trading and are expected to remain halted until after the Exchange has reviewed the materials in support of the Proposed Transaction.
Except for statements of historical fact, all statements in this press release, including, but not limited to, statements regarding future plans, objectives and payments are forward-looking statements that involve various risks and uncertainties.
For More Information
For more information about Canabo, please contact:
Completion of the Proposed Transaction is subject to a number of conditions, including but not limited to, Exchange acceptance. Where applicable, the Proposed Transaction cannot close until the required corporate approvals are obtained. There can be no assurance that the Proposed Transaction will be completed as proposed or at all.
The Exchange has in no way passed on the merits of the proposed Proposed Transaction and has neither approved nor disapproved the contents of this press release.
Neither Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements and information that are based on the beliefs of management and reflect the Company's current expectations. When used in this press release, the words 'estimate', 'project', 'belief', 'anticipate', 'intend', 'expect', 'plan', 'predict', 'may' or 'should' and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. The forward-looking statements and information in this press release includes information relating to the Proposed Transaction (including its structure and any required shareholder approval, shareholder support, and other terms), the Private Placement (including its completion and the use of proceeds from the Aleafia Private Placement), the directors and management of the Resulting Issuer upon completion of the Proposed Transaction, and the implementation of Aleafia's business plan. Such statements and information reflect the current view of the Company with respect to risks and uncertainties that may cause actual results to differ materially from those contemplated in those forward-looking statements and information.
By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: risks associated with the completion of the Proposed Transaction and matters relating thereto; and risks associated with the marketing and sale of securities, the need for additional financing, reliance on key personnel, the potential for conflicts of interest among certain officers or directors, and the volatility of the Company's common share price and volume. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements.
There are a number of important factors that could cause the Company's actual results to differ materially from those indicated or implied by forward-looking statements and information. Such factors include, among others, risks related to Aleafia's proposed business, such as failure of the business strategy and government regulation; risks related to Aleafia's operations, such as additional financing requirements and access to capital, reliance on key and qualified personnel, insurance, competition, intellectual property and reliable supply chains; risks related to Aleafia and its business generally. The Company cautions that the foregoing list of material factors is not exhaustive. When relying on the Company's forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. The Company has assumed a certain progression, which may not be realized. It has also assumed that the material factors referred to in the previous paragraph will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. While the Company may elect to, it does not undertake to update this information at any particular time.
THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS PRESS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS PRESS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
Click on, or paste the following link into your web browser, to view the associated documents http://www.newsfilecorp.com/release/31656
|Company:||Canabo Medical Inc.|
|End of News||DGAP News Service|
Der AKTIONÄR News
18. Januar 07:39 Neues Rekordkursziel: Goldman Sachs sicher - Infineon verdient ...
18. Januar 07:09 Egbert Prior: Diese Aktie strahlt immer heller
17. Januar 22:01 BASF-Finanzvorstand Engel: "Ein spannendes Programm für 2018"
17. Januar 22:00 Neue Ausgabe: Reiten Sie den Bullen! Die Top-Trends für 2018: ...
17. Januar 17:00 Faktor-Trade des Tages: Apple vor dem Mega-Kaufsignal
News im Fokus
Deutsche Börse AG: Bank Markazi reicht Klage gegen Deutsche Börse AG-Tochter Clearstream ein
18. Januar 2018, 00:10
Original-Research: ABO Invest AG (von First Berlin Equity Research GmbH): Buy
16. Januar 2018